Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy (Review)
- Authors:
- Yu Zhang
- Zi‑Yan Xie
- Xuan‑Tong Guo
- Xing‑Hua Xiao
- Li‑Xia Xiong
-
Affiliations: Department of Pathophysiology, Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Nanchang University, Nanchang, Jiangxi 330006, P.R. China - Published online on: July 22, 2019 https://doi.org/10.3892/ol.2019.10653
- Pages: 2743-2755
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wu Y, Shao A, Wang L, Hu K, Yu C, Pan C and Zhang S: The role of lncRNAs in the distant metastasis of breast cancer. Front Oncol. 9:4072019. View Article : Google Scholar : PubMed/NCBI | |
Spill F, Reynolds DS, Kamm RD and Zaman MH: Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 40:41–48. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wan L, Pantel K and Kang Y: Tumor metastasis: Moving new biological insights into the clinic. Nat Med. 19:1450–1464. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kozłowski J, Kozłowska A and Kocki J: Breast cancer metastasis-insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (Online). 69:447–451. 2014. View Article : Google Scholar | |
Bray SJ: Notch signalling in context. Nat Rev Mol Cell Biol. 17:722–735. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bray SJ: Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006. View Article : Google Scholar : PubMed/NCBI | |
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israël A: A novel proteolytic cleavage involved in Notch signaling: The role of the disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000. View Article : Google Scholar : PubMed/NCBI | |
Sprinzak D, Lakhanpal A, Lebon L, Santat LA, Fontes ME, Anderson GA, Garcia-Ojalvo J and Elowitz MB: Cis-interactions between Notch and Delta generate mutually exclusive signalling states. Nature. 465:86–90. 2010. View Article : Google Scholar : PubMed/NCBI | |
Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S and Griffin JD: MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 26:484–489. 2000. View Article : Google Scholar : PubMed/NCBI | |
D'Souza B, Miyamoto A and Weinmaster G: The many facets of Notch ligands. Oncogene. 27:5148–5167. 2008. View Article : Google Scholar : PubMed/NCBI | |
Visan I: Asymmetric division. Nature Immunol. 13:1202012. View Article : Google Scholar | |
Santoro A, Vlachou T, Carminati M, Pelicci PG and Mapelli M: Molecular mechanisms of asymmetric divisions in mammary stem cells. EMBO Rep. 17:1700–1720. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ and Visvader JE: Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell. 3:429–441. 2008. View Article : Google Scholar : PubMed/NCBI | |
Dontu G, Jackson KW, Mcnicholas E, Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6:R605–R615. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rhyu MS, Jan LY and Jan YN: Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell. 76:477–491. 1994. View Article : Google Scholar : PubMed/NCBI | |
McGill MA and McGlade CJ: Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem. 278:23196–23203. 2003. View Article : Google Scholar : PubMed/NCBI | |
Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and Hegardt C: The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10:R532008. View Article : Google Scholar : PubMed/NCBI | |
Calaf GM, Ponce-Cusi R and Abarca-Quinones J: Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer. Oncol Rep. 39:2741–2748. 2018.PubMed/NCBI | |
Huiping L, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, et al: Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA. 107:18115–18120. 2010. View Article : Google Scholar : PubMed/NCBI | |
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007. View Article : Google Scholar : PubMed/NCBI | |
Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, et al: Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. EMBO Mol Med. 5:1502–1522. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chakrabarti R, Wei Y, Romano RA, DeCoste C, Kang Y and Sinha S: Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells. 30:1496–1508. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li L, Guturi KKN, Gautreau B, Patel PS, Saad A, Morii M, Mateo F, Palomero L, Barbour H, Gomez A, et al: Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis. J Clin Invest. 128:4525–4542. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC and Werb Z: GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 13:141–152. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačišin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, et al: Elf5 inhibits epithelial mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 14:1212–1222. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lin HY, Liang YK, Dou XW, Chen CF, Wei XL, Zeng, Bai JW, Guo YX, Lin FF, Huang WH, et al: Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 7:592018. View Article : Google Scholar : PubMed/NCBI | |
Mack GS and Marshall A: Lost in migration. Nat Biotechnol. 28:214–229. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Li J, Cadilha BL, Markota A, Voigt C, Huang Z, Lin PP, Wang DD, Dai J, Kranz G, et al: Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv. 5:eaav42752019. View Article : Google Scholar : PubMed/NCBI | |
Shao S and Zhao X, Zhang X, Luo M, Zuo X, Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer. 14:282015. View Article : Google Scholar : PubMed/NCBI | |
Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I and Karsan A: Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 204:2935–2948. 2007. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Imanaka N, Chen J and Griffin JD: Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 102:351–360. 2010. View Article : Google Scholar : PubMed/NCBI | |
Jian J, Yang Q, Shao Y, Axelrod D, Smith J, Singh B, Krauter S, Chiriboga L, Yang Z, Li J and Huang X: A link between premenopausal iron deficiency and breast cancer malignancy. BMC Cancer. 13:3072013. View Article : Google Scholar : PubMed/NCBI | |
Liu L, Chen X, Wang Y, Qu Z, Lu Q, Zhao J, Yan X, Zhang H and Zhou Y: Notch3 is important for TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther. 21:364–372. 2014. View Article : Google Scholar : PubMed/NCBI | |
Bolos V, Mira E, Martinez-Poveda B, Luxán G, Cañamero M, Martínez-A C, Mañes S and de la Pompa JL: Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res. 15:R542013. View Article : Google Scholar : PubMed/NCBI | |
Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J and Brabletz T: The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 30:770–782. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhang X and Zhao X, Shao S, Zuo X, Ning Q, Luo M, Gu S and Zhao X: Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role. Int J Oncol. 46:1141–1148. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kim RK, Kaushik N, Suh Y, Yoo KC, Cui YH, Kim MJ, Lee HJ, Kim IG and Lee SJ: Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget. 7:53430–53442. 2016.PubMed/NCBI | |
Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling P, et al: Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene. 32:4892–4902. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Shao X, Sun H, Liu K, Ding Z, Chen J, Fang L, Su W, Hong Y and Li H and Li H: NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget. 7:61036–61053. 2016.PubMed/NCBI | |
Garcia-Heredia JM, Verdugo Sivianes EM, Lucena-Cacace A, Molina-Pinelo S and Carnero A: Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. Oncotarget. 7:63611–63628. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Fu L, Gu F and Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep. 26:1295–1303. 2011.PubMed/NCBI | |
Dou XW, Liang YK, Lin HY, Wei XL, Zhang YQ, Bai JW, Chen CF, Chen M, Du CW, Li YC, et al: Notch3 maintains luminal phenotype and suppresses tumorigenesis and metastasis of breast cancer via trans-activating estrogen receptor-alpha. Theranostics. 7:4041–4056. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI | |
Li L, Zhao F, Lu J, Li T, Yang H, Wu C and Liu Y: Notch-1 signaling promotes the malignant features of human breast cancer through NF-κB activation. PLoS One. 9:e959122014. View Article : Google Scholar : PubMed/NCBI | |
Mahmood N, Mihalcioiu C and Rabbani SA: Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, Prognostic, and therapeutic applications. Front Oncol. 8:242018. View Article : Google Scholar : PubMed/NCBI | |
Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW and Schildberg FW: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nat Med. 1:1035–1039. 1995. View Article : Google Scholar : PubMed/NCBI | |
Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res. 71:277–286. 2011. View Article : Google Scholar : PubMed/NCBI | |
Song J: Notch signaling mediates Tumor-CAF crosstalk in basal-like breast cancer. 2014. | |
Liu ZJ, Lsemenza G and Zhang HF: Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 16:32–43. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI | |
Semenza GL: HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 8 (Suppl 4):S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI | |
Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI | |
De EF, Maggiolini M and Musti AM: Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT. Int J Mol Sci. 19:20112018. View Article : Google Scholar | |
Lim SO, Kim HS, Quan X, Ahn SM, Kim H, Hsieh D, Seong JK and Jung G: Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol. 9:832011. View Article : Google Scholar : PubMed/NCBI | |
Boufraqech M, Zhang L, Nilubol N, Sadowski SM, Kotian S, Quezado M and Kebebew E: Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers. Clin Cancer Res. 22:4491–4504. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sahlgren C, Gustafsson MV, Jin S, Poellinger L and Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 105:6392–6397. 2008. View Article : Google Scholar : PubMed/NCBI | |
Villanueva MT: Metastasis: LOX does some prepping. Nat Rev Cancer. 15:3842015. View Article : Google Scholar : PubMed/NCBI | |
Deshmukh SK, Srivastava SK, Tyagi N, Ahmad A, Singh AP, Ghadhban AAL, Dyess DL, Carter JE, Dugger K and Singh S: Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: A closer look at the surroundings. Carcinogenesis. 38:757–765. 2017. View Article : Google Scholar : PubMed/NCBI | |
Aboussekhra A: Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol. 55:841–849. 2011. View Article : Google Scholar : PubMed/NCBI | |
Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas C, et al: Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol. 16:889–901. 2014. View Article : Google Scholar : PubMed/NCBI | |
Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 17:1193–1204. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cho OH, Shin HM, Miele L, Golde TE, Fauq A, Minter LM and Osborne BA: Notch regulates cytolytic effector function in CD8+ T cells. J Immunol. 182:3380–3389. 2009. View Article : Google Scholar : PubMed/NCBI | |
Qiu H, Zmina PM, Huang AY, Askew D and Bedogni B: Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. Cancer Lett. 434:144–151. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sugimoto K, Maekawa Y, Kitamura A, Nishida J, Koyanagi A, Yagita H, Kojima H, Chiba S, Shimada M and Yasutomo K: Notch2 signaling is required for potent antitumor immunity in vivo. J Immunol. 184:4673–4678. 2010. View Article : Google Scholar : PubMed/NCBI | |
Palaga T, Wongchana W and Kueanjinda P: Notch signaling in macrophages in the context of cancer immunity. Front Immunol. 9:6522018. View Article : Google Scholar : PubMed/NCBI | |
Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG and Li MO: The cellular and molecular origin of tumor-associated macrophages. Science. 344:921–925. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhao JL, Huang F, He F, Gao CC, Liang SQ, Ma PF, Dong GY, Han H and Qin HY: Forced activation of notch in macrophages represses tumor growth by upregulating miR-125a and disabling tumor-associated macrophages. Cancer Res. 76:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI | |
Zhou Z, Yao H and Hu H: Disrupting Tumor Angiogenesis and ‘the Hunger Games’ for Breast Cancer. Adv Exp Med Biol. 1026:1712017. View Article : Google Scholar : PubMed/NCBI | |
Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI | |
Cuervo H, Nielsen CM, Simonetto DA, Ferrell L, Shah VH and Wang RA: Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. Hepatology. 64:1302–1316. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kontomanolis EN, Kalagasidou S, Pouliliou S, Anthoulaki X, Georgiou N, Papamanolis V and Fasoulakis ZN: The notch pathway in breast cancer progression. ScientificWorldJournal. 2018:24154892018. View Article : Google Scholar : PubMed/NCBI | |
Blanco R and Gerhardt H: VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med. 3:a0065692013. View Article : Google Scholar : PubMed/NCBI | |
Siekmann AF, Covassin L and Lawson ND: Modulation of VEGF signalling output by the Notch pathway. Bioessays. 30:303–313. 2008. View Article : Google Scholar : PubMed/NCBI | |
Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 69:135–144. 2001. View Article : Google Scholar : PubMed/NCBI | |
Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 445:776–780. 2007. View Article : Google Scholar : PubMed/NCBI | |
Suchting S and Eichmann A: Jagged gives endothelial tip cells an edge. Cell. 137:988–990. 2009. View Article : Google Scholar : PubMed/NCBI | |
Phng LK and Gerhardt H: Angiogenesis: A team effort coordinated by notch. Dev Cell. 16:196–208. 2009. View Article : Google Scholar : PubMed/NCBI | |
Oon CE, Li JL, Sainson R, Sheldon H, Turley H, Leek R and Harris A: 360 Role of DLL4 and JAG1 in tumour angiogenesis. EJC Supplements. 8:92. 2010. View Article : Google Scholar | |
Panin VM, Papayannopoulos V, Wilson R and Irvine KD: Fringe modulates Notch-ligand interactions. Nature. 387:908–912. 1997. View Article : Google Scholar : PubMed/NCBI | |
Boareto M, Jolly MK, Ben-Jacob E and Onuchic JN: Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision. Proc Natl Acad Sci USA. 112:E3836–E3844. 2015. View Article : Google Scholar : PubMed/NCBI | |
Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M and Adams RH: The Notch Ligands Dll4 and Jagged1 have opposing effects on Angiogenesis. Cell. 137:1124–1135. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen JY, Li CF, Chu PY, Lai YS, Chen CH, Jiang SS, Hou MF and Hung WC: Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1. Oncotarget. 7:27689–27710. 2016.PubMed/NCBI | |
Rodriguez-Vita J and Fischer A: Notch signaling facilitates crossing of endothelial barriers by tumor cells. Mol Cell Oncol. 4:e13118282017. View Article : Google Scholar : PubMed/NCBI | |
White DE and Muller WJ: Multifaceted Roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 12:135–142. 2007. View Article : Google Scholar : PubMed/NCBI | |
Deford P, Brown K, Richards RL, King A, Newburn K, Westover K and Albig AR: MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis. Exp Cell Res. 341:84–91. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, Haslett C and Sethi T: Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol Chem. 282:28991–29001. 2007. View Article : Google Scholar : PubMed/NCBI | |
Liu B, Zheng X, Meng F, Han Y, Song Y, Liu F, Li S, Zhang L, Gu F, Zhang X and Fu L: Overexpression of β1 integrin contributes to polarity reversal and a poor prognosis of breast invasive micropapillary carcinoma. Oncotarget. 9:4338–4353. 2017.PubMed/NCBI | |
Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S and Klemke R: Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci. 123:2332–2341. 2010. View Article : Google Scholar : PubMed/NCBI | |
Guo P and Rafii S: Dangerous liaisons: Deviant endothelium NOTCHes toward tumor metastasis. Cancer Cell. 31:301–303. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lianidou ES and Markou A: Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem. 57:1242–1255. 2011. View Article : Google Scholar : PubMed/NCBI | |
Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC and Marchetti D: Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 8:1962017. View Article : Google Scholar : PubMed/NCBI | |
Portanova P, Notaro A, Pellerito O, Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol. 43:121–130. 2013. View Article : Google Scholar : PubMed/NCBI | |
Day TW, Huang S and Safa AR: c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol. 76:1694–1704. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kim JW, Kim MJ, Kim KJ, Yun HJ, Chae JS, Hwang SG, Chang TS, Park HS, Lee KW, Han PL, et al: Notch interferes with the scaffold function of JNK-interacting protein 1 to inhibit the JNK signaling pathway. Proc Natl Acad Sci USA. 102:14308–14313. 2005. View Article : Google Scholar : PubMed/NCBI | |
Archibald A, Mihai C, Macara IG and McCaffrey L: Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3. Oncogene. 34:3199–3206. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR and Sun SY: c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64:7570–7578. 2004. View Article : Google Scholar : PubMed/NCBI | |
Naik S, MacFarlane M and Sarin A: Notch4 signaling confers susceptibility to TRAIL-Induced Apoptosis in breast cancer cells. J Cell Biochem. 116:1371–1380. 2015. View Article : Google Scholar : PubMed/NCBI | |
Phipps LE, Hino S and Muschel RJ: Targeting cell spreading: A method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. Mol Cancer Res. 9:249–258. 2011. View Article : Google Scholar : PubMed/NCBI | |
Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP and Brennan K: Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res. 69:5015–5022. 2009. View Article : Google Scholar : PubMed/NCBI | |
Tao L, Roberts AL, Dunphy KA, Bigelow C, Yan H and Jerry DJ: Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity. Stem Cells. 29:119–127. 2011. View Article : Google Scholar : PubMed/NCBI | |
Su F, Zhu S, Ruan J, Muftuoglu Y, Zhang L and Yuan Q: Combination therapy of RY10-4 with the gamma-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget. 7:4142–4154. 2016.PubMed/NCBI | |
Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI | |
Li L, Zhang J, Xiong N, Li S, Chen Y, Yang H, Wu C, Zeng H and Liu Y: Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway. Med Oncol. 33:332016. View Article : Google Scholar : PubMed/NCBI | |
Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mungamuri SK, Yang X, Thor AD and Somasundaram K: Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 66:4715–4724. 2006. View Article : Google Scholar : PubMed/NCBI | |
Dotto GP: Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer. 9:587–595. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kim SB, Chae GW, Lee J, Park J, Tak H, Chung JH, Park TG, Ahn JK and Joe CO: Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ. 14:982–991. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cherdyntseva NV, Litviakov NV, Denisov EV, Gervas PA and Cherdyntsev ES: Circulating tumor cells in breast cancer: Functional heterogeneity, pathogenetic and clinical aspects. Exp Oncol. 39:2–11. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang P, He D, Chen Z, Pan Q, Du F, Zang X, Wang Y, Tang C, Li H, Lu H, et al: Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer. Biochem Pharmacol. 118:18–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, et al: Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-Dependent cancer stem cell activity. Cell Rep. 12:1968–1977. 2015. View Article : Google Scholar : PubMed/NCBI | |
Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, et al: Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 7:104422016. View Article : Google Scholar : PubMed/NCBI | |
Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, et al: Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 159:499–513. 2014. View Article : Google Scholar : PubMed/NCBI | |
Arteaga CL and Engelman JA: ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, et al: HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 537:102–106. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kang Y: Dissecting Tumor-Stromal interactions in breast cancer bone metastasis. Endocrinol Metab (Seoul). 31:206–212. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Wang H, Ikeda S, Fahey F, Bielenberg D, Smits P and Hauschka PV: Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol. 177:1459–1469. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sethi N, Dai X, Winter CG and Kang Y: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19:192–205. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lee JH and Welch DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 57:2384–2387. 1997.PubMed/NCBI | |
Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, et al: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 411:613–617. 2001. View Article : Google Scholar : PubMed/NCBI | |
Leone A, Flatow U, Vanhoutte K and Steeg PS: Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene. 8:2325–2333. 1993.PubMed/NCBI | |
Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F: The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest. 32:838–846. 2002. View Article : Google Scholar : PubMed/NCBI | |
Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI and Kim WH: Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer. 134:519–529. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ignesti M, Barraco M, Nallamothu G, Woolworth JA, Duchi S, Gargiulo G, Cavaliere V and Hsu T: Notch signaling during development requires the function of awd, the Drosophila homolog of human metastasis suppressor gene Nm23. BMC Biol. 12:122014. View Article : Google Scholar : PubMed/NCBI | |
Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E and Massagué J: Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 17:867–874. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wang XY, Penalva LO, Yuan H, Linnoila RI, Lu J, Okano H and Glazer RI: Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 9:2212010. View Article : Google Scholar : PubMed/NCBI | |
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G and Egan SE: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 65:8530–8537. 2005. View Article : Google Scholar : PubMed/NCBI | |
Tanabe H, Takayama I, Nishiyama T, Shimazaki M, Kii I, Li M, Amizuka N, Katsube K and Kudo A: Periostin associates with Notch1 precursor to maintain Notch1 expression under a stress condition in mouse cells. PLoS One. 5:e122342010. View Article : Google Scholar : PubMed/NCBI | |
Zhou M, Kawashima N, Suzuk N, Yamamoto M, Ohnishi K, Katsube K, Tanabe H, Kudo A, Saito M and Suda H: Periostin is a negative regulator of mineralization in the dental pulp tissue. Odontology. 103:152–159. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N and Kudo A: Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem. 285:2028–2039. 2010. View Article : Google Scholar : PubMed/NCBI | |
Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI | |
Aguirre Ghiso JA, Kovalski K and Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 147:89–104. 1999. View Article : Google Scholar : PubMed/NCBI | |
Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V, Tosello V, Basso G, Amadori A and Indraccolo S: Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia. 25:588–598. 2011. View Article : Google Scholar : PubMed/NCBI | |
Enderling H, Almog N and Hlatky L: Systems biology of tumor dormancy. Springer; New York: 2013, View Article : Google Scholar | |
Zhang Y, Li J, Lai XN, Jiao XQ, Xiong JP and Xiong LX: Focus on Cdc42 in Breast Cancer: New insights, target therapy development and non-coding RNAs. Cells. 8(pii): E1462019. View Article : Google Scholar : PubMed/NCBI | |
Ors-Kumoglu G, Gulce-Iz S and Biray-Avci C: Therapeutic microRNAs in human cancer. Cytotechnology. 71:411–425. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wu MY, Fu J, Xiao X, Wu J and Wu RC: MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett. 354:311–319. 2014. View Article : Google Scholar : PubMed/NCBI | |
Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH and Tang JH: MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res. 43:514–521. 2012. View Article : Google Scholar : PubMed/NCBI | |
Rui X, Zhao H, Xiao X, Wang L, Mo L and Yao Y: MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1. Exp Ther Med. 16:4387–4392. 2018.PubMed/NCBI | |
Lan L, Wang Y, Pan Z, Wang B, Yue Z, Jiang Z, Li L, Wang C and Tang H: Rhamnetin induces apoptosis in human breast cancer cells via the miR-34a/Notch-1 signaling pathway. Oncol Lett. 17:676–682. 2019.PubMed/NCBI | |
Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B and Li L: MiR-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci. 106:700–708. 2015. View Article : Google Scholar : PubMed/NCBI | |
Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 74:7573–7582. 2014. View Article : Google Scholar : PubMed/NCBI | |
Suman S, Das TP and Damodaran C: Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 109:2587–2596. 2013. View Article : Google Scholar : PubMed/NCBI | |
Heller G, Altenberger C, Steiner I, Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A, Zehetmayer S, Döme B, et al: DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients. J Pathol. 245:387–398. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li WJ, Xie XX, Bai J, Wang C, Zhao L and Jiang DQ: Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 22:8374–8382. 2018.PubMed/NCBI | |
Kong P, Chen L, Yu M, Tao J, Liu J, Wang Y, Pan H, Zhou W and Wang S: miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis. 9:10592018. View Article : Google Scholar : PubMed/NCBI | |
Mohammadi-Yeganeh S, Mansouri A and Paryan M: Targeting of miR9/NOTCH1 interaction reduces metastatic behavior in triple-negative breast cancer. Chem Biol Drug Des. 86:1185–1191. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liang YK, Lin HY, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, et al: MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. NPJ Breast Cancer. 4:202018. View Article : Google Scholar : PubMed/NCBI | |
Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR and Wajapeyee N: miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife. 3:e014602014. View Article : Google Scholar : PubMed/NCBI | |
Kuang W, Tan J, Duan Y, Duan J, Wang W, Jin F, Jin Z, Yuan X and Liu Y: Cyclic stretch induced miR-146a upregulation delays C2C12 myogenic differentiation through inhibition of Numb. Biochem Biophys Res Commun. 378:259–263. 2009. View Article : Google Scholar : PubMed/NCBI | |
Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M and Steeg PS: Breast cancer metastasis: Issues for the personalization of its prevention and treatment. Am J Pathol. 183:1084–1095. 2013. View Article : Google Scholar : PubMed/NCBI | |
Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, et al: Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget. 8:2320–2328. 2017. View Article : Google Scholar : PubMed/NCBI | |
Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A and Gupta S: Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 51:1865–1873. 2015. View Article : Google Scholar : PubMed/NCBI | |
Takebe N, Nguyen D and Yang SX: Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI | |
So JY, Wahler J, Das Gupta S, Salerno DM, Maehr H, Uskokovic M and Suh N: HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44+/CD24−/low tumor-initiating subpopulation in basal-like breast cancer. J Steroid Biochem Mol Biol. 148:111–121. 2015. View Article : Google Scholar : PubMed/NCBI | |
Krop IE, Kosh M, Fearen I, Savoie JG, Dallob AL, Matthews CK, Stone J, Winer EP, Freedman SJ and LoRusso PM: Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. Ann Oncol. 22:1413–1419. 2006. | |
Locatelli M and Curigliano G: Notch inhibitors and their role in the treatment of triple negative breast cancer: Promises and failures. Curr Opin Oncol. 29:411–427. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sanchez L, Muchene L, Lorenzo-Luaces P, Viada C, Rodriguez PC, Alfonso S, Crombet T, Neninger E, Shkedy Z and Lage A: Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. Semin Oncol. 45:52–57. 2018. View Article : Google Scholar : PubMed/NCBI | |
Makhoul I, Atiq M, Alwbari A and Kieber-Emmons T: Breast cancer immunotherapy: An update. Breast Cancer (Auckl). May 30–2018.(Epud ahead of print). doi: 10.1177/1178223418774802. View Article : Google Scholar | |
Gu X, Lu C, He D, Lu Y, Jin J, Liu D and Ma X: Notch3 negatively regulates chemoresistance in breast cancers. Tumour Biol. Oct 14–2016.(Epub ahead of print). View Article : Google Scholar | |
Lu X and Kang Y: Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci USA. 106:9385–9390. 2009. View Article : Google Scholar : PubMed/NCBI | |
Colombo M, Raposo G and Thery C: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al: Tumour exosome integrins determine organotropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lowry MC, Gallagher WM and O'Driscoll L: The role of exosomes in breast cancer. Clin Chem. 61:1457–1465. 2015. View Article : Google Scholar : PubMed/NCBI | |
Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N and Eberhart CG: The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clin Cancer Res. 16:6060–6070. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hanna A, Metge BJ, Bailey SK, Chen D, Chandrashekar DS, Varambally S, Samant RS and Shevde LA: Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. Oncoimmunology. 8:15482412018. View Article : Google Scholar : PubMed/NCBI |